Alembic Pharmaceuticals has announced its unaudited financial results for Q3 (Oct-Dec) of 2025, alongside the appointment of Mr. Rajkumar Baheti as a Non-Executive Non-Independent Director. Revenue from operations stood at ₹1,692.74 crore, and net profit reached ₹132.97 crore. Mr. Baheti’s appointment is effective April 1, 2026, following his tenure as an Executive Director.
Q3 Financial Highlights
Alembic Pharmaceuticals has released its unaudited consolidated financial results for the quarter and nine months ending December 31, 2025. Key financial figures from the report include:
- Revenue from operations: ₹1,692.74 crore
- Total Income: ₹1,891.81 crore
- Profit before tax: ₹161.50 crore
- Net Profit: ₹132.97 crore
The company reported earnings per share of ₹6.76 (Basic & Diluted).
Director Appointment
Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has appointed Mr. Rajkumar Baheti (DIN: 00332079) as a Non-Executive Non-Independent Director, effective April 1, 2026. He is liable to retire by rotation, subject to member approval via postal ballot.
Additional Financial Metrics
The announcement also included additional key financial metrics:
- Debt-Equity Ratio: 0.25
- Debt Service Coverage Ratio: 7.93
- Interest Service Coverage Ratio: 7.93
- Net Worth: ₹5,463.32 crore
- Operating Margin: 16.42%
Source: BSE
